Introduction and Context
Acute upper gastrointestinal bleeding (AUGIB) remains one of the most common and challenging medical emergencies worldwide. Defined by the sudden onset of symptoms such as haematemesis (vomiting blood), melaena (black, tarry stools), or haematochezia (bright red blood per rectum), it accounts for a significant proportion of emergency hospital admissions. For clinicians, AUGIB is a race against time, requiring rapid stabilization, accurate risk assessment, and often, urgent endoscopic intervention.
In the United Kingdom, the landscape of AUGIB management is periodically assessed through large-scale national audits. The most recent iteration, the 2022 UK Audit, comes fifteen years after its predecessor in 2007. Since that time, the medical landscape has shifted dramatically. The population is aging, the prevalence of multi-morbidity is rising, and the widespread use of direct oral anticoagulants (DOACs) has replaced older therapies. This updated audit provides a critical temperature check on how healthcare systems have adapted to these changes and where significant gaps in care still exist. This guideline-based summary explores the core findings of the 2022 audit and the expert consensus on how to further improve patient outcomes.
New Guideline Highlights
The 2022 audit, encompassing over 5,000 patients across 147 hospitals, reveals a healthcare environment under pressure but achieving notable successes. The headline finding is a paradoxical improvement in outcomes: despite patients being older, more comorbid, and more likely to be on high-risk medications, overall in-hospital mortality has decreased from 10.0% in 2007 to 8.8% in 2022. Rebleeding rates have also fallen from 13.3% to 9.7%.
However, the audit also highlights critical areas of non-adherence to national guidelines, particularly those set by the National Institute for Health and Care Excellence (NICE) and the British Society of Gastroenterology (BSG). Key takeaways for clinicians include:
- The Age of Complexity: The median age of patients is now 69, with a significantly higher prevalence of cirrhosis and anticoagulant use compared to 2007.
- Risk Stratification Gaps: Nearly 42% of patients did not undergo formal pre-endoscopic risk stratification, a critical step for identifying low-risk patients who could be managed as outpatients.
- The Danger of Over-Transfusion: A significant signal of harm was found in patients receiving “liberal” blood transfusions when their haemoglobin (Hb) levels were above 80 g/L, reinforcing the need for restrictive strategies.
- Shift in Salvage Therapy: When primary endoscopy fails, the medical community has shifted away from emergency surgery toward interventional radiology (IR) for arterial embolization.
Updated Recommendations and Key Changes
The following table summarizes the demographic and clinical shifts between the 2007 and 2022 audits, which drive the updated consensus on management.
| Metric | 2007 Audit Data | 2022 Audit Data | Clinical Implication |
|---|---|---|---|
| Median Age | 68 Years | 69 Years | Aging population with more fragility. |
| Comorbidity (any) | 50% | 67% | Higher baseline risk of death from non-GI causes. |
| Anticoagulant Use | 13% | 31% | Complexity in reversing bleeding and timing endoscopy. |
| In-hospital Mortality | 10.0% | 8.8% | Improved overall care and stabilization. |
| Rebleeding Rate | 13.3% | 9.7% | Better endoscopic techniques and PPI use. |
| Median Length of Stay | 6 Days | 5 Days | Increased efficiency in hospital throughput. |
Topic-by-Topic Recommendations
1. Risk Stratification and the Glasgow-Blatchford Score (GBS)
Expert consensus strongly advocates for the use of the Glasgow-Blatchford Score (GBS) at the point of presentation. A GBS of 0-1 identifies patients at very low risk of needing intervention or dying, allowing for safe discharge and outpatient follow-up. The 2022 audit found that 42% of patients were not risk-stratified. This is a significant clinical gap; improving GBS uptake can reduce unnecessary hospital admissions and focus resources on high-risk cases.
2. Restrictive Transfusion Strategy
One of the most vital findings of the 2022 update concerns blood transfusion thresholds. Current guidelines recommend a restrictive threshold: transfusion should generally be avoided unless Hb falls below 70 g/L (or 80 g/L in patients with pre-existing cardiovascular disease). The audit observed that 24% of transfusions were given inappropriately to haemodynamically stable patients. Crucially, the data showed that inappropriate transfusion at an Hb of 80 g/L was associated with a higher adjusted mortality (aOR 1.60). This reinforces the “less is more” approach in stable patients to avoid volume overload and portal pressure increases.
3. Endoscopy Timing and Intervention
The audit shows that 83% of patients now receive an endoscopy during their admission, up from 74% in 2007. Guidelines recommend endoscopy within 24 hours for most patients, and earlier for those with suspected variceal bleeding or haemodynamic instability. While the use of therapeutic endotherapy (like clips, thermal coagulation, or banding) remains modest (27%), the quality of the intervention has improved. For patients who “re-bleed,” the consensus has shifted heavily toward interventional radiology (IR) as the first-line salvage therapy rather than traditional surgery.
4. The Anticoagulant Challenge
With 31% of patients on anticoagulants, clinicians must balance the risk of life-threatening bleeding against the risk of thromboembolic events (like stroke) if medications are stopped. The audit found that anticoagulant use was independently associated with increased mortality (aOR 1.43). Updated guidelines emphasize the need for standardized reversal protocols and clear multidisciplinary decision-making on when to resume these life-saving but high-risk medications.
Expert Commentary and Insights
Experts involved in the 2022 audit suggest that the improvement in mortality despite a higher-risk population is a testament to the maturation of “bleeding bundles” and the establishment of dedicated gastrointestinal bleed units in many UK hospitals. However, the committee noted with concern the persistent “signal of harm” from liberal blood transfusions. “We are still seeing a culture of ‘reflex’ transfusion,” noted one lead auditor. “Changing this mindset is perhaps the most significant low-cost intervention we have left to further reduce mortality.”
Another area of controversy is the timing of endoscopy for stable patients. While some argue for ultra-early endoscopy (within 6 hours), the consensus remains that stabilization and resuscitation are the priorities. The audit data suggests that for the majority of non-variceal patients, a high-quality endoscopy within 24 hours is the appropriate standard of care, provided the patient is not in refractory shock.
Practical Implications and Patient Case
To illustrate the application of these findings, consider the case of “Robert,” a 75-year-old man who presents to the Emergency Department with melaena. He has a history of atrial fibrillation and takes apixaban (an anticoagulant). His blood pressure is stable, but his heart rate is slightly elevated. His Hb is 82 g/L.
Under the old paradigm, Robert might have received an immediate blood transfusion. However, according to the 2022 audit findings and current expert consensus:
- Action 1: Calculate GBS. Robert’s score is likely high due to age and symptoms, necessitating admission.
- Action 2: Withhold transfusion. Since his Hb is 82 g/L and he is haemodynamically stable, a restrictive strategy is safer. A transfusion at this level could increase his risk of mortality.
- Action 3: Schedule endoscopy within 24 hours. Robert should be prioritized for a daytime list where expert staff and equipment are readily available.
- Action 4: Multidisciplinary review. Cardiology and Gastroenterology must collaborate to decide when to restart his apixaban post-procedure.
By following these evidence-based steps, clinicians can continue the trend of improving outcomes for patients with AUGIB, ensuring that even as the patient population becomes more complex, the care provided remains precise, safe, and effective.
References
- Nigam GB, et al. Acute upper gastrointestinal bleeding in the UK: 2022 audit update. Gut. 2026;75(4):760-771. PMID: 41260910.
- National Institute for Health and Care Excellence (NICE). Acute upper gastrointestinal bleeding in over 16s: management. Clinical guideline [CG141].
- Tripathi D, et al. UK guidelines on the management of variceal haemorrhage in children and adults. Gut. 2015;64(11):1680-704.
- Lau JYW, et al. Management of Acute Upper Gastrointestinal Bleeding: An Updated International Consensus Recommendation. Annals of Internal Medicine. 2019;171(11):811-822.
